Ignite Creation Date:
2025-12-24 @ 4:31 PM
Ignite Modification Date:
2026-01-15 @ 6:38 PM
Study NCT ID:
NCT03759366
Status:
COMPLETED
Last Update Posted:
2024-12-11
First Post:
2018-11-26
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)
Sponsor:
Alexion Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-12-28
Start Date Type:
ACTUAL
Primary Completion Date:
2022-01-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-11-06
Completion Date Type:
ACTUAL
First Submit Date:
2018-11-26
First Submit QC Date:
None
Study First Post Date:
2018-11-30
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2022-08-01
Results First Submit QC Date:
None
Results First Post Date:
2022-08-25
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-12-04
Last Update Post Date:
2024-12-11
Last Update Post Date Type:
ACTUAL